During the recent decade, numerous epidemiologic studies [7–11] have assessed the association between PDE5 inhibitors used to treat ED and the risk of malignant melanoma, and a positive association (i.e., RR >1.00) was reported in three studies. This evidence concerns the gene PDE5A and melanoma.